200956-13-4

Basic information

• Product Name: 2-BROMO-4-(TRIFLUOROMETHOXY)PHENOL
• Synonyms: 2-BROMO-4-(TRIFLUOROMETHOXY)PHENOL;BUTTPARK 144\07-26;2-Bromo-4-(trifluoromethoxy)phenol 97%;2-Bromo-4-(trifluoromethoxy)phenol97%
• CAS NO: 200956-13-4
• Molecular Formula: C₇H₄BrF₃O₂
• Molecular Weight: 257
• Mol File: 200956-13-4.mol

Chemical Properties

• Boiling Point: 203.2±35.0 °C(Predicted)
• Appearance: /
• Density: 1.779±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 7.82±0.18(Predicted)
• CAS DataBase Reference: 2-BROMO-4-(TRIFLUOROMETHOXY)PHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-4-(TRIFLUOROMETHOXY)PHENOL(200956-13-4)
• EPA Substance Registry System: 2-BROMO-4-(TRIFLUOROMETHOXY)PHENOL(200956-13-4)

Safety Data

• Hazardous Substances Data: 200956-13-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-4-(trifluoromethoxy)phenol is used as a building block in organic synthesis for the development of new pharmaceutical products. Its antimicrobial and antifungal properties contribute to the creation of drugs that target various infections and diseases.
Used in Agrochemical Industry:
In the agrochemical industry, 2-Bromo-4-(trifluoromethoxy)phenol is used as a key component in the synthesis of herbicides. Its incorporation into these products helps in the effective control of unwanted plant growth, thereby enhancing crop productivity.
Used in Organic Synthesis:
2-Bromo-4-(trifluoromethoxy)phenol is utilized as an intermediate in the manufacture of specialty chemicals and other organic compounds. Its unique structure and properties make it a valuable component in the synthesis of a wide range of chemical products.
Overall, 2-Bromo-4-(trifluoromethoxy)phenol is a versatile and valuable chemical compound with applications spanning across various industries, particularly in the development and production of pharmaceuticals, agrochemicals, and specialty chemicals.

Upstream product

• 828-27-3 4-Trifluoromethoxyphenol 
• 7732-18-5 water 

Downstream Products

• 200956-14-5 2-bromo-1-methoxy-4-(trifluoromethoxy)benzene 
• 1416858-92-8 3-(2-bromo-4-(trifluoromethoxy)phenoxy)-2'-fluoro-4'-methoxybiphenyl-2-carbonitrile 
• 290832-43-8 2-methoxy-5-trifluoromethoxybenzeneboronic acid 
• 200953-37-3 (5R,6S)-3-(2-benzyloxy-5-(trifluorometoxy)phenyl)-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)azaspiro[4.5]dec-3-ene 
• 143582-95-0 4-benzyloxy-3-bromophenyl trifluoromethyl ether 

Relevant articles and documents

Use of NK-1 receptor antagonists for treating major depressive disorders

The present invention provides methods for the treatment of major depressive disorders comprising oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor

2-aryl indole derivative as antagonists of tachykinins

The present invention relates to compounds of the formula (I): wherein R1a, R1b, R2, R3, R4, R5, X and n are defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis and postherpetic neuralgia.

Stereocontrolled syntheses of epimeric 3-aryl-6-phenyl-1-oxa-7-azaspiro[4.5]decane NK-1 receptor antagonist precursors

Equation presented Complementary stereoselective syntheses of individual C3 epimers of the NK-1 receptor antagonist precursor 1 have been developed. Both diastereomers were derived from the common intermediate 3; introduction of the 3S stereocenter in 1a

Use of NK-1 receptor antagonists for treating stress disorders

The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of stress disorders without concomitant the

Phenyl spiroethercycloalkyl tachykinin receptor antagonists

The present invention is directed to certain novel compounds represented by structural formula I: STR1 or a pharmaceutically acceptable salt thereof, wherein R 3, R 6, R 7, R 8, R 11, R 12, R 13, m, n and the dashed lines are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis.

USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING BIPOLAR DISORDERS

The present invention provides methods for the treatment or prevention of bipolar disorder without concomitant therapy with other antidepressant or anti-anxiety agents which comprises oral administration of an orally active, long acting, CNS-penetrant NK-

1,3-benzoxazine derivatives, their production and use

A new compound of the formula: STR1 wherein STR2 is an optionally substituted benzene ring; R1 is a carbocyclic or heterocyclic group which is linked to the 4-position of the 1,3-benzoxazine ring through a carbon-carbon bond, a hydrocarbon resi